Skip to main content

Table 1 Model inputs

From: Comparative cost analysis of cervical cancer screening programme based on molecular detection of HPV in Spain

  AHPV versus HC2 AHPV versus Cobas 4800
AHPV HC2 AHPV Cobas
Transition probabilities (%)
Women 35–65 years
 HPV positive 7.5% [20] 11.5% [20] 7.5% [20] 12.4% [20]
 Abnormal LBC after HPV positive 31.1% [21] 38.5% [23] 31.1% [21] 35.6% [22]
Women 25–34 years
 Abnormal LBC 6.5% [21] 6.5% [21] 6.5% [21] 6.5% [21]
 ASC-US in patients with abnormal LBC 46.0% [21] 46.0% [21] 46.0% [21] 46.0% [21]
 HPV test positive in patients with ASC-US 42.0% [14] 53.0% [14] 53.0% [39] 58.2% [39]
 L-SIL + in patients with abnormal LBC 74.1% [40] 74.1% [40] 74.1% [40] 74.1% [40]
  Unit cost (± SD) References
Unit costs (€, 2019)
 HPV primary test € 31.81b [17, 25]
 HPV secondary test € 21.90c [17]
 LBC primary € 42.55 (± 12.13)a,d [17, 26]
 LBC secondary € 32.64 (± 12.13)a,e [26]
 Colposcopy and biopsy € 200.11 (± 2.73)a,f [24, 26]
  1. ASC-US+: any cytology result from atypical squamous cells of undetermined significance to carcinoma; AHPV: Aptima HPV Assay; HC2: Hybrid Capture 2 Assay; HPV: human papilloma virus; LBC: liquid-base cytology; L-SIL+: any cytology result from low-grade squamous intraepithelial lesions to carcinoma; SD: Standard deviation
  2. aAverage cost obtained from the list of references identified in the Spanish database
  3. bIncludes sample-taking costs (human resources, disposables and vial), costs of molecular detection of HPV processing and interpretation of results
  4. cIncludes costs of molecular detection of HPV processing and interpretation of results; 3. Includes sample-taking costs (human resources, disposables and vial), costs of cytology processing and interpretation
  5. dIncludes costs of cytology processing and interpretation
  6. eIncludes the colposcopy procedure with processing and interpretation of one biopsy